Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: Interim analysis of the restore extension study

Ophthalmology

Volumn 120, Issue 10, 2013, Pages 2004-2012

  Lang, Gabriele E ^a   Berta, András ^b   Eldem, Bora M ^c   Simader, Christian ^d   Sharp, Dianne ^e   Holz, Frank G ^f   Sutter, Florian ^g   Gerstner, Ortrud ^h   Mitchell, Paul ⁱ  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c HACETTEPE UNIVERSITY   (Turkey)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e GREEN LANE HOSPITAL   (New Zealand)

^f UNIVERSITY OF BONN   (Germany)

^g UNIVERSITÄTSSPITAL ZÜRICH   (Switzerland)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ARTHRALGIA; ARTICLE; BACKACHE; CATARACT; CENTRAL RETINAL THICKNESS; CEREBROVASCULAR ACCIDENT; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CORONARY ARTERY DISEASE; COUGHING; DEMOGRAPHY; DIABETIC MACULAR EDEMA; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOPHTHALMITIS; EYE DISCHARGE; EYE PAIN; FALLING; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; INFLUENZA; LACRIMATION; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE; OCULAR PRURITUS; OPEN STUDY; PAIN; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETREATMENT; RHINOPHARYNGITIS; SIDE EFFECT; SUBARACHNOID HEMORRHAGE; TREATMENT DURATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; VISUAL ACUITY;

EID: 84885022310     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.02.019     Document Type: Article

References (12)

1. N. Ferrara, L. Damico, and N. Shams Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 2006 859 870
2. European Medicines Agency. Lucentis: EPAR-Product Information. EMEA/H/C/000715-IB/0032. Updated July 20, 2012. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000715/WC500043546.pdf. Accessed February 1, 2013.
3. Diabetic Retinopathy Clinical Research Network, M.J. Elman, L.P. Aiello, and R.W. Beck Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 117 2010 1064 1077
4. Diabetic Retinopathy Clinical Research Network Writing Committee, M.J. Elman, N.M. Bressler, and H. Qin Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 118 2011 609 614
5. P. Massin, F. Bandello, and J.G. Garweg Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study Diabetes Care 33 2010 2399 2405
6. P. Mitchell, F. Bandello, U. Schmidt-Erfurth RESTORE Study Group The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema Ophthalmology 118 2011 615 625
7. Q.D. Nguyen, S.M. Shah, J.S. Heier READ-2 Study Group Primary end point (six months): results of the Ranibizumab for Edema of the Macula in Diabetes (READ-2) study Ophthalmology 116 2009 2175 2181
8. Q.D. Nguyen, S.M. Shah, A.A. Khwaja READ-2 Study Group Two-year outcomes of the Ranibizumab for Edema of the Macula in Diabetes (READ-2) study Ophthalmology 117 2010 2146 2151
9. Q.D. Nguyen, D.M. Brown, D.M. Marcus RISE and RIDE Research Group Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE Ophthalmology 119 2012 789 801
10. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1 Arch Ophthalmol 103 1985 1796 1806
11. C.M. Mangione, P.P. Lee, and P.R. Gutierrez National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-list-item National Eye Institute Visual Function Questionnaire Arch Ophthalmol 119 2001 1050 1058
12. F. Bandello, J. Cunha-Vaz, and N.V. Chong New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel Eye (Lond) 26 2012 485 493